The single dose of the Chinese firm CanSino It will apply to adults between the ages of 18 and 60. It will be available at vaccination centers nationwide and will target two groups. To those who have not received any dose against the covid-19 and to those who became ill in the last six months and were unable to access the immunization.
The information was released by the Ministry of Public Health (MSP) this Tuesday, August 24, 2021.
The decision was made due to the last scientific studies carried out in the world on the total coverage in people infected months ago, that is, it reached 100%.
# Vaccination Plan9100 | Due to the community presence of variants of concern, especially Delta, @Health_Ec redefined the vaccination strategy in the application of CanSino and AstraZeneca, in order to protect the population more quickly → https://t.co/5wY4kOAuAR pic.twitter.com/jvot4QvQsY
– Ministry of Public Health (@Salud_Ec) August 24, 2021
The single dose also applies to those who reside in hard-to-reach areas and in mobility situation in the country.
What is its effectiveness? In the Guidelines for the expansion of recombinant vaccine of adenovirus type 5 vector (Convidecia) against SARS-CoV-2 virus CanSino Biologics explains that the efficacy rate of the vaccine is 68.83% to prevent symptomatic cases, 14 days after dose placement. While it reaches the 95,47% for the prevention of serious illness, in the same period of time.
Similar percentages were observed in countries like Chile. The formula reaches a 95% effectiveness for serious pictures of the disease; plus 65% in symptomatic pathology.
Until this Mars, August 24, Ecuador has received 500,000 formulas from this Chinese firm. Of these, 44 776 have already been applied, according to the Vaccumometer, with cut to Monday, August 23, 2021.
–
